Bright Minds Biosciences (DRUG) is finishing 2024 as one of the best-performing small-cap stocks, posting a remarkable 2400% increase in the share price in the last quarter. News of the firm’s collaboration with Firefly Neuroscience (AIFF) on a groundbreaking Phase 2 study on a treatment for drug-resistant epilepsy catapulted the company, and investors have taken notice. Animal spirits may be elevating the shares, as the company still has a long journey ahead to profitability. Investors are advised to proceed cautiously, especially given the current frothy valuation.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Pursuing a Promising Pipeline Candidate
Bright Minds is a biotechnology company developing therapeutics for severe and life-altering brain diseases. Its broad portfolio of new chemical entities (NCEs) aims to treat diverse pain indications, seizures, and neuropsychiatric disorders. Its lead product candidates are targeted therapies specifically intended for individual patient populations. The company has also developed a unique platform of selective serotonergic agonists for different serotonergic receptors, expanding its NCE programs within neurology and psychiatry.
The company announced a collaboration with AI company Firefly Neuroscience to provide a complete analysis of the electroencephalogram (EEG) data in Bright Mind’s BREAKTHROUGH study, which is a Phase 2 clinical trial exploring the safety, efficacy, and tolerability of BMB-101, a 5-HT2Creceptor agonist, in adults suffering from Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).
Bright Minds and Firefly have previously cooperated to successfully analyze the data of Bright Mind’s first-in-human Phase 1 study of BMB-101 using Firefly’s BNA technology platform.
In other news, Bright Minds recently closed a non-brokered private placement of 1,612,902 common shares at $21.70 per share, raising $35 million. These funds will be used for research and development related to its drug development programs and general working capital. Notable participants in the offering included Cormorant Asset Management, RA Capital Management, Perceptive Advisors, and Janus Henderson Investors.
Is DRUG a Buy?
The stock has been highly volatile, with a beta of 5.82. It trades near the middle of its 52-week price range of $0.93 – $79.02 and shows mixed technical indicators. The company trades at a lofty valuation, with its price-to-book (P/B) ratio of 37.13x well above the Healthcare sector average of 2.3x.
Wall Street is thinly following the company, though Robert W. Baird’s five-star analyst, Joel Beatty, has recently initiated coverage. He assigns the shares an Outperform rating with a price target of $75. He sees potential for substantial gains on the results from the BREAKTHROUGH trial, which are expected in mid-2025.
Based on his recommendation, Bright Minds Biosciences is rated a Moderate Buy with a price target for DRUG stock of $75.00, representing a potential upside of 101.31% from current levels.
Bottom Line on Bright Minds
Bright Minds Biosciences made waves with a remarkable increase in its shares last quarter, thanks to a promising and innovative collaboration with Firefly Neuroscience. However, as exciting as this rapid growth may be, potential investors should approach the high-risk, high-potential reward opportunity with caution due to the company’s current high valuation.
